Fig. 6: Neurog2 knockdown suppresses orthotopic tumors in NEPC models.
From: A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer
A (Top) Representative images of tumors established by orthotopic engraftment of LASCPC01 cells transduced by lentiviruses expressing shRFP or shNeurog2; (Bottom left) NEUROG2 knockdown in shNeurog2 transduced LASCPC-01 cells (data presented as mean ± SE; n = 3; standard ‘t’ test; ***p < 0.001); (Bottom right) quantification of tumor sizes (data presented as mean ± SE; n = 6 for shRFP and n = 6 for shNeurog2; one animal did not form measurable tumor in shNeurog2 (not included); standard ‘t’ test; *p < 0.05). B (Top) Representative images of tumors established by orthotopic engraftment of 22-MYC cells transduced by lentiviruses expressing shRFP or shNeurog2; (Bottom left) NEUROG2 knockdown in shNeurog2 transduced 22-MYC cells (data presented as mean ± SE; n = 3; standard ‘t’ test; ***p < 0.001); (Bottom right) quantification of tumor sizes (data presented as mean ± SE; n = 3; standard ‘t’ test; *p < 0.05).
